Rogers James William sold $2.7M of TEM

Rogers James William (Chief Financial Officer) sold 48,842 shares of Tempus AI, Inc. (TEM) at an average of $55.21 ($49.61–$60.00, $2.70M total) across 2 trades over 2026-08-18 to 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rogers James William
Published Aug 21, 2026, 1:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 1:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Bearish
medium confidence
Mentioned
$TEM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMBearishLow
01

Why it matters

The sale may cause a short‑term dip but is unlikely to alter the company's fundamentals.

02

Market read

Insider sales are watched by traders; this filing provides fresh data for short‑term positioning.

03

What to watch

The 10b5‑1 plan pre‑arranges sales, reducing the informational value of the transaction.

Relevance 5/10Novelty 6/10Timing: filing date 2026‑08‑20

Background

Form 4 filing from Tempus AI, Inc. discloses an insider sale by the CFO.

Company-level read

Ticker impact

$TEMBearishMedium confidence
Context

CFO Rogers James William sold 48,842 shares for $2.7M via a 10b5‑1 plan, reducing his stake to 106,024 shares.

Expected impact

Potential modest downside of 1‑2% over the next few days.

Evidence & confidence

A $2.7M sale by a senior officer is material for a $200M‑market‑cap stock, but the transaction was pre‑arranged and not unusual.

Market effects

Minimal impact on the broader AI/health‑tech sector.

Limited to U.S. investors tracking insider activity.

No significant global effect.

Counterpoint

The sale could be purely liquidity‑driven; the CFO may still be bullish on long‑term prospects.

Key entities

  • Tempus AI, Inc.

    AI‑driven healthcare data platform listed on NASDAQ (TEM).

  • Rogers James William

    Chief Financial Officer of Tempus AI.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.